Evidence map›Paper›PMID 38953636›Full record

ArticlemBio2024

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.

Mehdi Benlarbi, Shilei Ding, Étienne Bélanger, Alexandra Tauzin, Raphaël Poujol, Halima Medjahed, Omar El Ferri, Yuxia Bo, Catherine Bourassa, Julie Hussin and 6 more

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Will COVID-19 become mild, like a cold?Epidemiology and infection · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mehdi BenlarbiCentre de Recherche du CHUM, Montréal, Québec, Canada.ORCID 0000-0001-9966-3784
Shilei DingCentre de Recherche du CHUM, Montréal, Québec, Canada.
Étienne BélangerCentre de Recherche du CHUM, Montréal, Québec, Canada.
Alexandra TauzinCentre de Recherche du CHUM, Montréal, Québec, Canada.
Raphaël PoujolMontreal Heart Institute, Research Center, Montreal, Quebec, Canada.
Halima MedjahedCentre de Recherche du CHUM, Montréal, Québec, Canada.
Omar El FerriDepartment of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.
Yuxia BoDepartment of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.
Catherine BourassaCentre de Recherche du CHUM, Montréal, Québec, Canada.
Julie HussinMontreal Heart Institute, Research Center, Montreal, Quebec, Canada.
Judith FafardLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada.
Marzena PazgierInfectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.ORCID 0000-0003-0594-5057
Inès LevadeLaboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada.
Cameron AbramsDepartment of Biochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA.
Marceline CôtéDepartment of Biochemistry, Microbiology and Immunology, Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, Ontario, Canada.
Andrés FinziCentre de Recherche du CHUM, Montréal, Québec, Canada.ORCID 0000-0002-4992-5288

Funding

Canada Research Chair on Retroviral Entry RCHS0235CIHR FellowshipCIHR foundation grant 352417CIHR operating Pandemic and Health Emergencies Research grant 177958CIHR Project grant 174924Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) 41027Fondation du CHUMFRQS Junior 2 research scholarMinistère de l'Économie et de l'Innovation du Québec, Programme de soutien aux organismes de recherche et d'innovationMITACS Elevation postdoctoral fellowshipSentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Québec Santé (FRQS)Tier II Canada Research Chair in Molecular Virology and Antiviral Therapeutics 950-232424
6 · The paper itself

Abstract

The continued evolution of severe acute respiratory syndrome 2 (SARS-CoV-2) requires persistent monitoring of its subvariants. Omicron subvariants are responsible for the vast majority of SARS-CoV-2 infections worldwide, with XBB and BA.2.86 sublineages representing more than 90% of circulating strains as of January 2024. To better understand parameters involved in viral transmission, we characterized the functional properties of Spike glycoproteins from BA.2.75, CH.1.1, DV.7.1, BA.4/5, BQ.1.1, XBB, XBB.1, XBB.1.16, XBB.1.5, FD.1.1, EG.5.1, HK.3, BA.2.86 and JN.1. We tested their capacity to evade plasma-mediated recognition and neutralization, binding to angiotensin-converting enzyme 2 (ACE2), their susceptibility to cold inactivation, Spike processing, as well as the impact of temperature on Spike-ACE2 interaction. We found that compared to the early wild-type (D614G) strain, most Omicron subvariants' Spike glycoproteins evolved to escape recognition and neutralization by plasma from individuals who received a fifth dose of bivalent (BA.1 or BA.4/5) mRNA vaccine and improve ACE2 binding, particularly at low temperatures. Moreover, BA.2.86 had the best affinity for ACE2 at all temperatures tested. We found that Omicron subvariants' Spike processing is associated with their susceptibility to cold inactivation. Intriguingly, we found that Spike-ACE2 binding at low temperature was significantly associated with growth rates of Omicron subvariants in humans. Overall, we report that Spikes from newly emerged Omicron subvariants are relatively more stable and resistant to plasma-mediated neutralization, present improved affinity for ACE2 which is associated, particularly at low temperatures, with their growth rates.IMPORTANCEThe persistent evolution of SARS-CoV-2 gave rise to a wide range of variants harboring new mutations in their Spike glycoproteins. Several factors have been associated with viral transmission and fitness such as plasma-neutralization escape and ACE2 interaction. To better understand whether additional factors could be of importance in SARS-CoV-2 variants' transmission, we characterize the functional properties of Spike glycoproteins from several Omicron subvariants. We found that the Spike glycoprotein of Omicron subvariants presents an improved escape from plasma-mediated recognition and neutralization, Spike processing, and ACE2 binding which was further improved at low temperature. Intriguingly, Spike-ACE2 interaction at low temperature is strongly associated with viral growth rate, as such, low temperatures could represent another parameter affecting viral transmission.

Indexed as

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusTemperatureAntibodies, NeutralizingHumansProtein BindingACE2 protein, humanAngiotensin-Converting Enzyme 2Antibodies, NeutralizingSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2ACE2 bindinghumoral responsesOmicron subvariantsSARS-CoV-2temperature

Identifiers

PMID38953636
PMCPMC11323525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.